Patent application number | Description | Published |
20090068642 | Composition and pharmacology of novel alpha6-containing nicotinic acetylcholine receptors - Nicotinic acetylcholine receptors (nAChRs) comprising the α6 receptor subunit; nucleic acids, including vectors, comprising subunit incoding sequences; cells expressing the nAChRs of the invention; and methods of screening compounds are provided. | 03-12-2009 |
20100028447 | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs - The present invention generally relates to pharmaceutical compositions for the intranasal, buccal, or sublingual administration of metanicotine analogs. | 02-04-2010 |
20110257224 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUO- ROBENZAMIDE - The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetyl-choline receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS). | 10-20-2011 |
20110262407 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS - The present invention includes methods, uses, and selective alpha7 nAChR ligands for treating or preventing disease and disorders in which stimulation of neurogenesis is ameliorative; namely, wherein the recruitment of neurogenesis is therapeutic. | 10-27-2011 |
20120157477 | REVERSAL OF L-DOPA-INDUCED DYSKINESIA BY NEURONAL NICOTINIC RECEPTOR LIGANDS - The present invention includes methods, uses, and compounds for treating or preventing L-dopa-induced dyskinesias. | 06-21-2012 |
20140163065 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S, 3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBE- NZAMIDE - The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS). | 06-12-2014 |
20140234270 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS - The present invention includes methods, uses, and selective alpha7 nAChR ligands for treating or preventing disease and disorders in which stimulation of neurogenesis is ameliorative; namely, wherein the recruitment of neurogenesis is therapeutic. | 08-21-2014 |